UPCC 05817: A Phase II Trial of Nivolumab plus Ipilimumab in Men with Metastatic Castration Resistant Prostate Cancer
-
- STATUS
- None
Updated on 19 February 2024
Summary
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of a combination of two investigational drugs called nivolumab (also known as BMS-936558) and ipilimumab (BMS-734016) in subjects with advanced prostate cancer.
Details
| Condition | TBD, tbd, tbd |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | 02985957 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.